Get the Stockscreener App
5.59
2.61%
-0.15
After Hours:
5.59
Forte Biosciences Inc stock is traded at $5.59, with a volume of 13,555.
It is down -2.61% in the last 24 hours and down -29.24% over the past month.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA).
See More
Previous Close:
$5.74
Open:
$5.63
24h Volume:
13,555
Relative Volume:
1.92
Market Cap:
$8.16M
Revenue:
-
Net Income/Loss:
$-31.48M
P/E Ratio:
-4.819
EPS:
-1.16
Net Cash Flow:
$-28.71M
1W Performance:
-20.54%
1M Performance:
-29.24%
6M Performance:
-67.88%
1Y Performance:
-66.22%
1-Day Range:
$5.295
$5.79
1-Week Range:
$4.86
$7.00
52-Week Range:
$4.86
$21.25
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
When the Price of (FBRX) Talks, People Listen - Stock Traders Daily
FBRX stock touches 52-week low at $6.47 amid market challenges - Investing.com
FBRX stock touches 52-week low at $6.47 amid market challenges - Investing.com Canada
FBRX stock touches 52-week low at $6.47 amid market challenges - Investing.com Australia
FBRX stock touches 52-week low at $6.47 amid market challenges - Investing.com India
Forte Biosciences reshuffles board, settles lawsuit - Investing.com India
Forte Biosciences reshuffles board, settles lawsuit By Investing.com - Investing.com Australia
Forte Biosciences reshuffles board, settles lawsuit - Investing.com
Forte Biosciences Welcomes New Directors Amidst Strategic Changes - TipRanks
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.39% - MSN
Traders Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
(FBRX) Long Term Investment Analysis - Stock Traders Daily
FBRX stock touches 52-week low at $6.9 amid market challenges - Investing.com
FBRX stock touches 52-week low at $6.9 amid market challenges - Investing.com India
FBRX stock touches 52-week low at $6.9 amid market challenges - Investing.com UK
Mind Medicine (MindMed) (OTCMKTS:MMEDF) Trading 5.9% Higher - Defense World
FORTE BIOSCIENCES INC. Trade Ideas — MUN:37T - TradingView
Forte Biosciences executes reverse stock split - Investing.com
Forte Biosciences, Inc. (NASDAQ:FBRX) Sees Significant Growth in Short Interest - MarketBeat
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.39% - MSN
FBRX stock touches 52-week high at $8.62 amid market fluctuations - Investing.com Canada
FBRX stock touches 52-week high at $8.62 amid market fluctuations - Investing.com India
FBRX stock touches 52-week high at $8.62 amid market fluctuations - Investing.com
Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested - EMEA Tribune, Breaking News, World News, Latest News, Top Headlines
Upcoming Stock Splits This Week (August 26 to August 30) – Stay InvestingTHE BHARAT EXPRESS NEWS - The Bharat Express News
Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested - Nasdaq
Upcoming Stock Splits This Week (August 26 to August 30) – Stay Invested - TipRanks
Forte Biosciences announces stockholder-approved equity plan By Investing.com - Investing.com Australia
Forte Biosciences announces stockholder-approved equity plan - Investing.com
Forte Biosciences announces stockholder-approved equity plan By Investing.com - Investing.com UK
Forte Biosciences: Key Outcomes from 2024 Stockholders Meeting - TipRanks
Verona Pharma plc (VRP.L) (LON:VRP) Stock Price Crosses Above Two Hundred Day Moving Average of $55.00 - Defense World
FY2024 EPS Estimates for Forte Biosciences, Inc. Decreased by Analyst (NASDAQ:FBRX) - Defense World
Autoliv, Inc. (NYSE:ALV) Shares Purchased by SG Americas Securities LLC - Defense World
Lexicon Pharmaceuticals’ (LXRX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Augean (LON:AUG) Shares Cross Below 200 Day Moving Average of $371.00 - Defense World
Nisa Investment Advisors LLC Has $1.81 Million Stock Position in Whirlpool Co. (NYSE:WHR) - Defense World
First Savings Financial Group (NASDAQ:FSFG) Stock Price Passes Above Two Hundred Day Moving Average of $17.50 - Defense World
Smart Powerr (NASDAQ:CREG) Stock Price Passes Below Two Hundred Day Moving Average of $1.14 - Defense World
Tectonic Therapeutic (NASDAQ:TECX) Research Coverage Started at Wells Fargo & Company - Defense World
Target (NYSE:TGT) PT Raised to $160.00 at Evercore ISI - Defense World
Dell Technologies Inc. (NYSE:DELL) Shares Bought by Raymond James Financial Services Advisors Inc. - Defense World
Vermilion Energy (NYSE:VET) Share Price Crosses Below Two Hundred Day Moving Average of $11.34 - Defense World
Synectics (LON:SNX) Shares Cross Above 200 Day Moving Average of $181.43 - Defense World
Traders Buy High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World
Booz Allen Hamilton (NYSE:BAH) and Ipsos (OTCMKTS:IPSOF) Head-To-Head Analysis - Defense World
Alopecia Areata Clinical Trials 2024: FDA Approvals, Pipeline, - openPR
Chardan Capital Reaffirms Buy Rating for Forte Biosciences (NASDAQ:FBRX) - Defense World
Forte Capital LLC ADV Sells 6,478 Shares of Apple Inc. (NASDAQ:AAPL) - Defense World
FBRX stock touches 52-week low at $0.37 amid market challenges - Investing.com Australia
Ratio Analysis: Unpacking Forte Biosciences Inc (FBRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):